

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
IFN.USPT.	3539
IFNS.USPT.	343
INTERFERON.USPT.	11042
INTERFERONS.USPT.	4553
COMBINATION.USPT.	1102104
COMBINATIONS.USPT.	337789
COMBINED.USPT.	687489
COMBINEDS.USPT.	1
COMPOSITION.USPT.	568895
COMPSN.USPT.	203
COMPSNS.USPT.	43
((IFN OR INTERFERON) SAME (COMBINATION OR COMBINED) SAME (COMPOSITION) SAME (ANTIBIOTIC) SAME (CHEMOTHERAPEUTIC)).USPT.	20

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Thursday, October 10, 2002 [Printable Copy](#) [Create Case](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
IFN.USPT.	3539
IFNS.USPT.	343
INTERFERON.USPT.	11042
INTERFERONS.USPT.	4553
COMBINATION.USPT.	1102104
COMBINATIONS.USPT.	337789
COMBINED.USPT.	687489
COMBINEDS.USPT.	1
COMPOSITION.USPT.	568895
COMPSN.USPT.	203
COMPSNS.USPT.	43
((IFN OR INTERFERON) SAME (COMBINATION OR COMBINED) SAME (COMPOSITION) SAME (ANTIBIOTIC) SAME (CHEMOTHERAPEUTIC)).USPT.	20

[There are more results than shown above. Click here to view the entire set.](#)

US Patents Full-Text Database

US Pre-Grant Publication Full-Text Database

JPO Abstracts Database

EPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Database:**Search:**

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Thursday, October 10, 2002 [Printable Copy](#) [Create Case](#)

WEST

[Help](#)
[Logout](#)
[Interrupt](#)
[Main Menu](#)
[Search Form](#)
[Posting Counts](#)
[Show S Numbers](#)
[Edit S Numbers](#)
[Preferences](#)
[Cases](#)

Search Results -

Term	Documents
GAMMA.USPT.	127188
GAMMAS.USPT.	551
(3 SAME GAMMA).USPT.	23
(L3 SAME GAMMA).USPT.	23

Database:

- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search:

L4

[Refine Search](#)
[Recall Text](#)
[Clear](#)

Search History

DATE: Thursday, October 10, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L4</u>	L3 same gamma	23	<u>L4</u>
<u>L3</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	<u>L3</u>
<u>L2</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	<u>L2</u>
<u>L1</u>	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show 8 Numbers](#)[Edit 8 Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
GAMMA.USPT.	127188
GAMMAS.USPT.	551
(3 SAME GAMMA).USPT.	23
(L3 SAME GAMMA).USPT.	23

Database:

[US Patents Full-Text Database](#)
[US Pre-Grant Publication Full-Text Database](#)
[JPO Abstracts Database](#)
[EPO Abstracts Database](#)
[Derwent World Patents Index](#)
[IBM Technical Disclosure Bulletins](#)

Search:

L4

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Thursday, October 10, 2002
[Printable Copy](#)
[Create Case](#)
Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L4</u>	L3 same gamma	23	<u>L4</u>
<u>L3</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	<u>L3</u>
<u>L2</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	<u>L2</u>
<u>L1</u>	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	<u>L1</u>

END OF SEARCH HISTORY

C12-L04

ABEQ US 5019382 A UPAB: 19930923

In an improved method of treating infectious disease of viral origin in human, canine and feline species, about 0.01 to about 5 IU, pref. 0.1-4.0 IU of interferon per lb of body wt. per dose, is contacted with the oral and pharyngeal mucosa of the species.

Pref. the interferon is alpha- or beta-interferon, esp. alpha-interferon produced from human leukocytes.

Pref. the treated viral infection is human rhinovirus, herpes, simplex I virus, herpes simplex II virus, viral myocarditis or HIV III virus (AIDS).

ADVANTAGE - Remission is effected of neoplastic disease, hyperallergenicity, immuno-resistant viral infections etc..

ABEQ EP 341258 B UPAB: 19940418

A composition comprising interferon and a pharmaceutically acceptable carrier therefore, in an effervescent tablet form adapted for dissolution in water to form a mouthwash or gargle formulation for human patient use for stimulating an immunotherapeutic response in said patient, said effervescent tablets containing 1 to 1500 IU of interferon.

Dwg.0/0

L119 ANSWER 27 OF 31 WPIX (C) 2002 THOMSON DERWENT

AN 1987-251462 [36] WPIX

DNC C1987-106397

TI Synergistic antiviral compsn. contg. interferon at low dose - plus tumour necrosis factor or lymphotoxin, esp. for treating and preventing aids.

DC B04 C03

IN WONG, G H; WONG, G H W

PA (GETH) GENENTECH INC

CYC 23

PI EP 235906 A 19870909 (198736)* EN 27p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE

AU 8767962 A 19870730 (198737)

JP 62215535 A 19870922 (198743)

DK 8700371 A 19870725 (198746)

GB 2194146 A 19880302 (198809)

HU 43957 T 19880128 (198810)

PT 84869 A 19880729 (198835)

ZA 8700470 A 19880722 (198844)

CN 87100480 A 19871111 (198846)

DD 263234 A 19881228 (198922)

US 4828830 A 19890509 (198922) 13p

EP 235906 B 19900926 (199039)

R: AT BE CH DE ES FR GB GR IT LI LU NL SE

DE 3765137 G 19901031 (199045)

CA 1296252 C 19920225 (199214)

ES 2031882 T3 19930101 (199305)

A61K037-66

DK 169234 B 19940919 (199436)

A61K037-66

JP 2510181 B2 19960626 (199630)

A61K038-21

<--

ADT EP 235906 A EP 1987-300589 19870123; JP 62215535 A JP 1987-15030 19870123;
GB 2194146 A GB 1987-11424 19870514; ZA 8700470 A ZA 1987-470 19870122; ES
2031882 T3 EP 1987-300589 19870123; DK 169234 B DK 1987-371 19870123; JP
2510181 B2 JP 1987-15030 19870123

FDT ES 2031882 T3 Based on EP 235906; DK 169234 B Previous Publ. DK 8700371;
JP 2510181 B2 Previous Publ. JP 62215535

PRAI US 1986-892531 19860731; US 1986-822099 19860124

REP DE 3227262; EP 128009; EP 131789; EP 170843; WO 8603751

IC ICM A61K037-66; A61K038-21

ICS A61K009-12; A61K037-02; A61K038-00; A61K038-44; A61K039-42;
A61K045-02; C12N007-00

ICI A61K037-66, A61K037:

AB EP 235906 A UPAB: 19970502

WO 1986-US2783 19861222, EP 1987-902456 19861222; CA 1323564 C CA
1987-545085 19870821

FDT EP 253887 B1 Based on WO 8704076; DE 3688841 G Based on EP 253887, Based
on WO 8704076

PRAI US 1985-814317 19851230

REP FR 2537436; FR 2575655; WO 8200588; 5.Jnl.Ref; 10Jnl.Ref

IC A61K039-26; A61K045-02

ICM A61K037-66; A61K039-39

ICS A61K039-26; A61K039-265; A61K045-02

AB WO 8704076 A UPAB: 19931116

Efficiency of a vaccine in warm-blooded vertebrates is enhanced by admin.
in conjunction with admin. of a vaccine contg. a biologically active
interferon (I) in a dosage up to 5 IU/lb body wt.

(I) is pref. administered at 1 IU/lb daily. It is suitably human
interferon-alpha. The first vaccine pref. is of the type used to confer
protection against bovine respiratory disease complex in cattle. It may
contain infectious bovine rhinotracheitis (IBR) virus, other viruses,
bacteria, mycoplasma, chlamydia, etc. With IBR vaccine, dosages of 10 to
the power 5.5-6.0 TCD 50/ml are normally used. With (I) the dosage should
allow redn. of the dosage by a factor of 10 to 100.

USE/ADVANTAGE - When (I) is used, the amount of killed or attenuated
micro-organisms needed to give an effective vaccination dose can be
reduced, so that the chances of detrimental vaccine infection are reduced.
The vaccine may also be obtained more economically. There may also be a quicker
antibody response. (I) is pref. administered orally, but parenteral,
intranasal and other routes may be used. Admin. may be simultaneously with
the first vaccine or up to one day before or after. For simultaneous
admin., the two vaccines may be combined or used separately. (I) has been
used in antiviral and antitumour therapy and as an immunomodulatory agent.
Dwg.0/0

FS CPI

FA AB

MC CPI: B02-V02; B02-V03; B12-A01; B12-A06; B12-D02B; B12-G07;
C02-V02; C02-V03; C12-A01; C12-A06; C12-D02B; C12-G07

ABEQ US 4820514 A UPAB: 19930922

A method of enhancing efficiency of vaccine comprises of co-admin. less
than 5 (pref. 1.0) IU/lb of interferon p.o. Interferon may be homo- or
hetero-logous for animals, pref. human alpha interferon for humans.

ADVANTAGE - Reduces amt of vaccine required by 10-100 fold and is of
economic importance in prevention or treatment of cattle BRDC.

ABEQ EP 253887 B UPAB: 19931118

A combination for vaccinating a warm-blooded vertebrate, including: a
vaccine for inducing immunity to an infectious disease; and at least one
dose of a biologically active interferon in a dosage form for oral
administration in an amount no greater than 5 IU of interferon/lb (11
IU/kg) of body weight of said vertebrate per unit dose; in which
combination the vaccine and the dose of interferon are optionally in a
form for independent administration.

Dwg.0/0

L119 ANSWER 29 OF 31 WPIX (C) 2002 THOMSON DERWENT

AN 1986-340015 [52] WPIX

CR 1986-101073 [16]; 1986-101574 [16]; 1986-126252 [20]; 1986-132434 [21];
1987-023031 [04]

DNC C1986-147364

TI Gamma-interferon low dosage use -

for treatment of auto immune diseases, virus infections and malignant
diseases.

DC B04

IN BRZOSKA, J; EICHBORN, J F; OBERT, H J

PA (BIOF-N) BIOFERON BIOCHEM SU

CYC 1

PI DE 3608608 A 19861218 (198652)* 24p

ADT DE 3608608 A DE 1986-3608608 19860314
 PRAI EP 1985-112625 19851004; EP 1985-107490 19850618; EP 1985-111184
 19850904
 IC A61K045-02
 AB DE 3608608 A UPAB: 19971113
 Use of **gamma-interferon (IFN-gamma)**
) in a daily dosage (based on adult patients of ca 60kg bodyweight and 1.7
 metres body surface) of 0.1-2 million international reference units (IU) or
 ca 10-200 microgrammes at daily to monthly intervals for the systemic
 treatment of autoimmune diseases, virus diseases and malignant diseases of
 humans is new.
 USE/ADVANTAGE - **Low dosages of IFN-**
gamma are effective against autoimmune diseases (e.g. multiple
 sclerosis, amyotrophic lateral sclerosis, Crohn's disease, asthma,
 allergies, psoriasis and non-rheumatic pains), viral diseases and
 malignant diseases. Higher doses are less effective.
 Dwg.0/0
 FS CPI
 FA AB
 MC CPI: B02-V03; B12-A06; B12-A07; B12-C10;
 B12-D01; B12-D02; B12-D07; B12-E02;
 B12-G07; B12-K02

L119 ANSWER 30 OF 31 WPIX (C) 2002 THOMSON DERWENT
 AN 1986-218778 [34] WPIX
 CR 1984-153736 [25]
 DNC C1986-094317
 TI **Low dosage interferon** administration to warm
 blooded vertebrates - to increase food utilisation efficiency and treat
 various bovine conditions.
 DC B04 C03
 IN **CUMMINS, J M**
 PA (TEXA) UNIV TEXAS A & M SYSTEM
 CYC 7
 PI AU 8551630 A 19860710 (198634)* 43p
 FR 2575655 A 19860711 (198634)
 DE 3600083 A 19860918 (198639)
 BR 8600071 A 19860923 (198645)
 ZA 8509894 A 19861021 (198704)
 US 4820515 A 19890411 (198917)
 IT 1207573 B 19890525 (199133)
 DE 3645343 A1 19960321 (199617) A23K001-16
 DE 3600083 C2 19960725 (199634) 20p A61K038-21 <--
 DE 3645343 C2 19971120 (199750) 18p A23K001-16
 US 5910304 A 19990608 (199930) A61K038-21 <--

ADT AU 8551630 A AU 1985-51630 19851224; FR 2575655 A FR 1986-46 19860103; DE
 3600083 A DE 1986-3600083 19860103; ZA 8509894 A ZA 1985-9894 19851230; US
 4820515 A US 1985-688868 19850104; DE 3645343 A1 Div ex DE 1986-3600083
 19860103; DE 1986-3645343 19860103; DE 3600083 C2 DE 1986-3600083
 19860103; DE 3645343 C2 Div ex DE 1986-3600083 19860103; DE 1986-3645343
 19860103; US 5910304 A CIP of US 1982-448951 19821213, Cont of US
 1985-688868 19850104, Cont of US 1987-44317 19870430, US 1992-875630
 19920428
 FDT DE 3645343 A1 Div ex DE 3600083; DE 3600083 C2 Div in DE 3645343; DE
 3645343 C2 Div ex DE 3600083; US 5910304 A CIP of US 4497795, Cont of US
 4820515
 PRAI US 1985-688868 19850104; US 1982-448951 19821213; US 1987-44317
 19870430; US 1992-875630 19920428
 IC A23K001-16; A23L000-00; A61K045-02
 ICM A23K001-16; A61K038-21
 ICS A23K001-165; A23L000-00; A61K045-02
 AB AU 8551630 A UPAB: 19960503
 A biologically active **interferon** is administered to warm-blooded

vertebrates in a daily dosage of at most about 5 IU/lb body wt. Cpd. is pref. of human **interferon** alpha, orally at a daily dosage of 0.1-1.5 IU/lb. for 3 consecutive days. The administration can be to bovine, porcine, caprine, ovine, avian feline, canine and equine animals, as well as humans.

USE/ADVANTAGE - The administration may be for (i) increasing the efficiency of food utilisation; (ii) preventing and treating bovine respiratory disease; (iii) treating a ship-stressed cow; or (iv) preventing and treating infectious bovine rhino tracheitis. The dosages are much smaller than those previously used.

0/0

Dwg.0/0

FS CPI

FA AB

MC CPI: B02-V03; B12-K06; B12-L09; C02-V03;

C12-K06; C12-L09

ABEQ US 4820515 A UPAB: 19930922

Increasing the appetite and efficiency of food utilisation in warm-blooded vertebrates comprises admin. (pref. oral) of a biologically active **interferon** (pref. human **interferon** alpha) in a dosage not greater than 5 IU (pref. 0.1-1.5 IU or 3 consecutive days) per lb. of body wt. per day.

ADVANTAGE - Much lower doses can be used than were previously.

L119 ANSWER 31 OF 31 WPIX (C) 2002 THOMSON DERWENT

AN 1986-101574 [16] WPIX

CR 1986-101073 [16]; 1986-126252 [20]; 1986-132434 [21]; 1986-340015 [52]; 1987-023031 [04]

DNC C1986-043441

TI Systemic treatment of human disease with **low doses** of **gamma interferon** - e.g. for control of tumours, virus disease, psoriasis and allergy.

DC B04

IN EICHBORN, J; LINK, F; OBERT, H; BRZOSKA, J; EICHBORN, J F; OBERT, H J; VON, EICHBORN J

PA (BIOF-N) BIOFERON BIOCHEM SU; (BIOF-N) BIOFERON BIOCHEM SUBSTANZ; (RENT) RENTSCHLER BIOTECHNOLOGIE GMBH; (BIOF-N) BIOFERON BIOCHEM; (BIOF-N) BIOFERON BICHEMISCHE SUBSTANZEN GMBH

CYC 18

PI EP 177910 A 19860416 (198616)* DE 22p

R: AT BE CH DE FR GB IT LI LU NL SE

DE 3436638 A 19860417 (198617)

AU 8548408 A 19860410 (198622)

AU 8548412 A 19860410 (198622)

JP 61091135 A 19860509 (198625)

JP 61093130 A 19860512 (198625)

DK 8504524 A 19860406 (198627)

DE 3436638 C 19860814 (198633)

ZA 8507721 A 19860731 (198644)

DE 3521733 A 19861218 (198652)

DE 3546568 A 19870723 (198730)

DE 3572441 G 19890928 (198940)

DE 3521733 C 19910411 (199115)

IL 76591 A 19910610 (199130)

DE 3583849 G 19910926 (199140)

CA 1288694 C 19910910 (199141)

DE 3448450 A 19920423 (199218)

DE 3448460 A 19920730 (199232)

US 5145677 A 19920908 (199239)

JP 05044930 B 19930707 (199330)

JP 2662214 B2 19971008 (199745)

JP 10087506 A 19980407 (199824)

JP 11255665 A 19990921 (199950)

8p A61K037-66

8p A61K037-66

6p A61K037-66

6p A61K038-21 <--

8p A61K038-21 <--

8p A61K038-21 <--

ADT DE 3436638 A DE 1984-3436638 19841005; JP 61091135 A JP 1985-188689 19850829; JP 61093130 A JP 1985-218143 19851002; DE 3436638 C DE 1985-3521733 19850618; ZA 8507721 A ZA 1985-7721 19851007; DE 3521733 A DE 1985-3546568 19850618; DE 3448450 A DE 1984-3448450 19841005; DE 3448460 A Div ex DE 1984-3436638 19841005, DE 1984-3448460 19841005; US 5145677 A Cont of US 1985-784419 19851004, US 1990-510714 19900418; JP 05044930 B JP 1985-188689 19850829; JP 2662214 B2 JP 1985-218143 19851002; JP 10087506 A Div ex JP 1985-218143 19851002, JP 1997-61337 19851002; JP 11255665 A Div ex JP 1997-61337 19851002, JP 1998-339113 19851002

FDT DE 3448450 A Div ex DE 3436638; DE 3448460 A Div ex DE 3436638; JP 05044930 B Based on JP 61091135; JP 2662214 B2 Previous Publ. JP 61093130

PRAI DE 1985-3521733 19850618; DE 1984-3436637 19841005; DE 1984-3436638 19841005; DE 1984-3448450 19841005; DE 1984-3448460 19841005; EP 1985-107490 19850618

REP No-SR.Pub

IC ICM A61K037-66; A61K038-21

ICS A61K009-08; A61K031-00; A61K031-70; A61K035-14; A61K045-02; C07K015-00

ICA C12N015-09; C12P021-02

AB EP 177910 A UPAB: 19991201

The use of **gamma interferon** (I) contg. compsns. for systemic treatment of human diseases is new. The daily dose is 0.1-2 million IU (10-200 microg) for a patient of 60 kg body wt. and 1.7 sq.m. body surface area, and the treatment is administered at daily to monthly intervals.

USE - The method is specified for: treatment of tumours (solid tumours or malignant haematological systemic diseases); recidivist prophylaxis of tumours; treatment and prophylaxis of acute or chronic virus diseases; treatment of diseases, esp. condylomata acuminata, caused by human papilloma virus; and treatment of psoriasis, allergies (esp. bronchial asthma), Crohn disease, amyotrophic lateral sclerosis, multiple sclerosis and pain.

Dwg.0/0

FS CPI

FA AB

MC CPI: B02-V03; B12-A06; B12-A07; B12-C10; B12-D01; B12-D02; B12-E02; B12-G07; B12-J01; B12-K02

ABEQ DE 3436638 C UPAB: 19930922

Pharmaceutical compsn. for the treatment of rheumatic illnesses comprises **gamma-interferon** and opt. other **interferons** and/or active prods. generated by leucocytes, dispersed with the usual carriers and opt. additives. These preps. contain 1 ng- 10 mg **gamma-interferon**, and are suitable for intravenous, intramuscular, subcutaneous, intracutaneous, intra-articular or intrathecal administration.

USE - The prods. are valuable therapeutics, esp. for the treatment of inflammatory, degenerative and extra-articular rheumatism or chronic polyarthrititis.

ABEQ DE 3521733 C UPAB: 19930922

Use of **interferon-gamma** preps. is claimed to treat amyotrophic lateral sclerosis. The preps. contains 20,000-2,000,000 international reference units (IE) per doses, corresp. to 2-200 micro g **interferon**. The prepn. opt. contains other **interferons** and/or cell mediators formed from leukocytes, produced e.g. by gene technology. The preps. are used for intravenous, intramuscular or subcutaneous application, or as nasal- or inhalation-sprays or sublingual tablets.

USE/ADVANTAGE - Amyotrophic lateral sclerosis is a disease due to degeneration of neurons of the CNS concerned with voluntary movement. It may opt. be caused by a slow virus.

In an example patient with ALS was treated with 0.1 x 10 power 5 IE **interferon-gamma** increasing to 1 x 10 power 6 IE 3 times

WEST



Generate Collection

Print

L3: Entry 39 of 134

File: USPT

Feb 27, 2001

DOCUMENT-IDENTIFIER: US 6193966 B1

TITLE: Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies

Detailed Description Text (66):

The compounds of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject in vivo. In a preferred embodiment, the pharmaceutical composition comprises either a multispecific molecule (compound, or agent) of the invention and a pharmaceutically acceptable carrier. In yet another embodiment of the present invention, the pharmaceutical composition can be administered by combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one anti-cancer agent, at least one antibiotic, at least one cytokine, at least one vaccine, or other conventional therapy. Exemplary anti-cancer agents include cis-platin, adriamycin, and taxol. Exemplary antibiotics include isoniazid, rifamycin, and tetracycline. Exemplary cytokines include G-CSF, GM-CSF, interleukins and interferons.

↑
column 25, line 18-30

600/ 103

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ .

<u>L5</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic) same (chemotherapeutic)	20	<u>L5</u>
<u>L4</u>	L3 same gamma	23	<u>L4</u>
<u>L3</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	<u>L3</u>
<u>L2</u>	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	<u>L2</u>
<u>L1</u>	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:38:37 ON 10 OCT 2002)

FILE 'USPATFULL' ENTERED AT 12:38:49 ON 10 OCT 2002

L1 54 S (INTERFERON (W) GAMMA)/CLM AND (PHARMACEUTICAL COMPOSITION)/C
L2 9 S L1 AND (ANTIBIOTIC? OR CHEMOTHER? OR ANTIFUNG? OR ANTIFIBRO?)

=> d bib,kwic 1-9

L2 ANSWER 1 OF 9 USPATFULL

AN 2002:259486 USPATFULL

TI Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes

IN Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES

Tari, Ana M., Houston, TX, UNITED STATES

Lim, Soo-Jeong, Seoul, KOREA, REPUBLIC OF

PA Board of Regents, The University of Texas System (U.S. corporation)

PI US 2002/143062 A1 20021003

AI US 2001-982113 A1 20011017 (9)

PRAI US 2000-241445P 20001017 (60)

DT Utility

FS APPLICATION

LREP FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED LIABILITY PARTNERSHIP,
Suite 2400, 600 Congress Avenue, Austin, TX, 78701

CLMN Number of Claims: 130

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3985

CLM What is claimed is:

12. The method of claim 11, wherein the anticancer agent is
chemotherapy agent, a radiotherapy agent, an immune therapy
agent, a genetic therapy agent, a hormonal therapy agent, a biological
agent, an. . .

44. The **pharmaceutical composition** of claim 43,
wherein said dimyristoyl phosphatidylcholine and soybean oil comprise a
ratio of greater than 80:20.

45. The **pharmaceutical composition** of claim 43,
wherein said composition further comprises at least one additional
agent.

46. The **pharmaceutical composition** of claim 45,
wherein said agent further comprises a linking moiety attached to said
agent and one or more lipids. . .

47. The **pharmaceutical composition** of claim 45,
wherein said agent comprises a targeting agent.

48. The **pharmaceutical composition** of claim 47,
wherein said targeting agent comprises at least one antibody to a tumor.

49. The **pharmaceutical composition** of claim 45,
wherein said agent comprises an additional therapeutic agent.

50. The **pharmaceutical composition** of claim 49,
wherein said additional therapeutic agent comprises an anticancer agent.

51. The method of claim 50, wherein the anticancer agent is
chemotherapy agent, a radiotherapy agent, an immune therapy
agent, a genetic therapy agent, a hormonal therapy agent, a biological
agent, an. . .

52. The **pharmaceutical composition** of claim 43,
wherein said composition is comprised as a lyophilized material.

53. The **pharmaceutical composition** of claim 43,
wherein said composition is comprised in a pharmaceutically acceptable

WEST Search History

DATE: Thursday, October 10, 2002

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

L13	L2 with (pharmaceutical composition).clm	143	L13
L12	L8 same (antibiotic\$ or chemother\$ or antifung\$ or antifibro\$).clm	12	L12
L11	L8 same dosa\$	4	L11
L10	L8 with (dosa\$)	2	L10
L9	L8 with (dosa\$ from 10 to 50,000 IU)	5	L9
L8	L2 with (pharmaceutical composition)	143	L8
L7	L2 same (pharmaceutical composition)	349	L7
L6	L5 and (from 10 to 10000IU)	1663	L6
L5	L4 and dosage	1670	L5
L4	L2 and (pharmaceutical composition)	2532	L4
L3	L2 and (pharmaceutical composition).clm	2532	L3
L2	(interferon)adj(gamma).clm	2828	L2
L1	interferon adj gamma.clm	0	L1

END OF SEARCH HISTORY

a week over 4 weeks and 0.5 x 10 power 6 IE once a week for 4 weeks. During therapy, the function of the upper extremities improved, with stretching and bending of the hands and elbows becoming opt.. The shoulders could also be moved slightly.

ABEQ US 5145677 A UPAB: 19930922

Therapeutic compsn. comprises natural and/or recombinant **gamma-interferone** and/or their active derivs. dispersed with the usual carriers and opt. additives. The active dosage is 10-200 micro-g daily.

USE - The prods. are therapeutics for neoplastic diseases, tumours, carcinomas, sarcomas, myelomas, lymphomas, papillomas, malignant haematological systemic diseases, Crohn's disease, degenerative illnesses, viral diseases, asthma, allergies, psoriasis and painful conditions, etc.

0/0

ABEQ JP 93044930 B UPAB: 19931118

The use of **gamma interferon** (I) contg. compsns. for systemic treatment of human diseases is new. The daily dose is 0.1-2 million IU (10-200 microg) for a patient of 60 kg body wt. and 1.7 sq.m. body surface area, and the treatment is administered at daily to monthly intervals.

USE - The method is specified for treatment of tumours (solid tumours or malignant haematological systemic diseases); recidivist prophylaxis of tumours; treatment and prophylaxis of acute or chronic virus diseases; treatment of diseases, esp. condylomata acuminata, caused by human papilloma virus; and treatment of psoriasis, allergies (esp. bronchial asthma), Crohn's disease, amyotrophic lateral sclerosis, multiple sclerosis and pain. (J61091135-A)

=> d his

(FILE 'HOME' ENTERED AT 10:06:22 ON 20 AUG 2002)
SET COST OFF

FILE 'MEDLINE' ENTERED AT 10:08:54 ON 20 AUG 2002

```

E INTERFERON/CT
E E76+ALL
E E2+ALL
L1      26801 S E53+NT
L2      26801 S E53/CN OR E71/CN
L3      38601 S (INTERFERON OR IFN) (S) GAMMA
L4      24236 S (INTERFERON OR IFN) (S) TYPE II
L5      42541 S L1-L4
L6      32130 S L5 AND PY<=1999
L7      1967 S L1 (L) TU./CT
L8      11093 S L1 (L) PD./CT
L9      789 S L1 (L) AD./CT
L10     11980 S L7-L9
L11     1036 S IFNGAMMA
L12     29 S GAMMAIFN
L13     512 S L11,L12 AND PY<=1999
L14     32242 S L6,L13
L15     10193 S L14 AND L10
L16     5414 S L15 AND L1/MAJ
L17     369 S L16 NOT AB/FA
L18     5045 S L16 NOT L17
L19     498 S L9 AND L18
L20     3479 S L18 NOT INTERFERON-GAMMA, RECOMBINANT/CT,CN
L21     130 S L9/MAJ AND L20
L22     130 S L21 AND (DOSE OR DOSAGE)
          E DOSE-RESPONSE/CT
          E E4+ALL
L23     176912 S E3+NT

```

L24 20 S L23 AND L22
 L25 11 S L24 AND C4./CT
 L26 2 S L24 AND (C2. OR C3.)/CT
 L27 0 S L24 AND C1./CT
 L28 4 S L24 AND (C5. OR C6. OR C7. OR C8. OR C9. OR C10.)/CT
 L29 6 S L24 AND (C11. OR C12. OR C13. OR C14. OR C15. OR C16. OR C17.
 L30 4 S L24 AND (C21. OR C22. OR C23.)/CT
 L31 20 S L24-L30
 L32 10 S L31 AND A11./CT
 L33 126 S L22 AND (C1. OR C2. OR C3. OR C4. OR C5. OR C6. OR C7. OR C8.
 L34 6 S L33 AND ?INFLAM?
 L35 66 S L20 AND LOW DOSE
 L36 1 S L20 AND LOW DOSAGE
 L37 66 S L35,L36
 L38 14 S L37 AND L23
 L39 4 S L38 AND C4./CT
 L40 30 S L37 AND C4./CT
 L41 30 S L39,L40
 L42 17 S L41 NOT RECOMBINANT
 L43 16 S L42 NOT CLONOGENIC/TI
 L44 26 S L32,L43
 L45 8 S L31 NOT L44
 L46 34 S L44,L45
 L47 34 S L46 AND L1-L46
 L48 517 S L14 AND ACUTE(S) ?INFLAM?
 L49 4291 S L14 AND MONOCYT?
 L50 1049 S L14 AND NEUTROPHIL
 L51 2433 S L14 AND B CELL
 L52 1741 S L14 AND B LYMPHOCYTE
 L53 6010 S L14 AND C4./CT
 L54 579 S L14 AND INFLAMMATION+NT/CT
 L55 1434 S L14 AND B-LYMPHOCYTES+NT/CT
 L56 2171 S L14 AND MONOCYTES+NT/CT
 L57 631 S L14 AND NEUTROPHILS+NT/CT
 L58 4138 S L14 AND (C1. OR C3.)/CT
 L59 2660 S L14 AND B3./CT
 L60 378 S L14 AND B5./CT
 L61 37 S L14 AND FIBROSIS+NT/CT
 L62 5650 S L14 AND C20./CT
 L63 19877 S L48-L62
 L64 675 S L63 AND L23
 L65 272 S L64 AND L1/MAJ
 L66 233 S L65 AND (L7/MAJ OR L8/MAJ OR L9/MAJ)
 L67 17 S L66 AND LOW() (DOSE OR DOSAGE)
 L68 48 S L47,L67 AND L1-L67
 L69 28 S L68 AND A11./CT
 L70 48 S L68,L69
 L71 19 S L14 AND REPERFUSION INJURY+NT/CT
 L72 66 S L71,L70
 L73 53 S L1/MAJ AND L72

FILE 'MEDLINE' ENTERED AT 10:41:13 ON 20 AUG 2002

FILE 'WPIX' ENTERED AT 10:41:55 ON 20 AUG 2002

L74 1530 S L11 OR L12 OR L3 OR L4
 L75 36 S INF(S) GAMMA
 L76 2 S INFGAMMA OR GAMMAINF
 L77 1539 S L74-L76
 L78 70 S C07K014-57/IC, ICM, ICS
 L79 19 S C07K014-57/ICA, ICI
 L80 0 S C07K014:57/ICI
 L81 870 S A61K038-21/IC, ICM, ICS
 L82 105 S A61K038-21/ICA, ICI

L83 18 S A61K038:21/ICI
L84 2298 S L77-L83
L85 183 S (B04-H05C OR C04-H05C)/MC
L86 799 S (B02-V03 OR C02-V03)/MC
L87 2860 S L84-L86
E R12268+ALL/DCN
L88 196 S E1
L89 2882 S L87,L88
L90 14 S L89 AND (LOZENG? OR PASTIL? OR TROCHE? OR SUCK? OR CONFECTION
L91 10 S L90 AND A61K038/IC, ICM, ICS
L92 4 S L90 NOT L91
L93 8 S L89 AND (AMENTO ? OR CUMMINS ?)/AU
L94 15 S L91,L93
L95 1416 S L89 AND (P220 OR P241 OR P420 OR P431 OR P633 OR P714 OR P820
L96 618 S L89 AND (B14-A01? OR C14-A01? OR B12-A0? OR C12-A0? OR B14-A0
L97 295 S L89 AND (B14-C03 OR C14-C03 OR B12-D07 OR C12-D07)/MC
L98 841 S L89 AND (B14-H01 OR C14-H01 OR B12-G07 OR C12-G07)/MC
L99 213 S L89 AND (B14-K01# OR C14-K01# OR B12-K06 OR C12-K06 OR B12-D0
L100 55 S L89 AND (B14-N01 OR C14-N01 OR B12-J08 OR C12-J08)/MC
L101 11 S L95-L100 AND L94
L102 11 S L101 AND INTERFERON
L103 3 S L102 AND GAMMA
L104 12 S L94,L101,L102 NOT L103
L105 1 S L104 AND GAMMA
L106 4 S L103,L105
L107 11 S L94,L101-L105 NOT L106
L108 31 S L89 AND LOW() (DOSE OR DOSAGE)
L109 5 S L108 AND L94
L110 23 S L108 AND L95-L100
L111 28 S L106,L109,L110
L112 6 S L108 NOT L111
L113 1 S L112 AND ORAL REMEDY
L114 29 S L111,L113
L115 14 S L114 AND (?INTERFERON? OR IFN OR INF) (L)GAMMA
L116 15 S L114 NOT L115
L117 11 S L116 AND INTERFERON
L118 25 S L115,L117
L119 31 S L93,L118

FILE 'WPIX' ENTERED AT 11:04:06 ON 20 AUG 2002